KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.

Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li, Min Yan, Zhongsheng Tong, Man Li, Yue'e Teng, Christina Pimentel Oppermann, Govind Babu Kanakasetty, Ma Coccia Portugal, Liu Yang, Wanli Zhang, Zefei Jiang

Chin Med J (Engl) 138(12) 1477-1486

PMID39385327
PMCIDPMC12180841
DOI10.1097/CM9.0000000000003151
发表日期2024-10-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+/HER2- advanced breast cancer (ABC). This study presents the final pre-planned PFS analysis. METHODS: In the phase III MONARCH plus study, postmenopausal women in China, India, Brazil, and South Africa with HR+/HER2- ABC without prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) were randomized (2:1) to abemaciclib (150 mg twice daily [BID]) or placebo plus: anastrozole (1.0 mg/day) or letrozole (2.5 mg/day) (cohort A) or fulvestrant (500 mg on days 1 and 15 of cycle 1 and then on day 1 of each subsequent cycle) (cohort B). The primary endpoint was PFS of cohort A. Secondary endpoints included cohort B PFS (key secondary endpoint), ORR, overall survival (OS), safety, and health-related quality of life (HRQoL). RESULTS: In cohort A (abemaciclib: n = 207; placebo: n = 99), abemaciclib plus a non-steroidal aromatase inhibitor improved median PFS vs . placebo (28.27 months vs . 14.73 months, hazard ratio [HR]: 0.476; 95% confidence interval [95% CI]: 0.348-0.649). In cohort B (abemaciclib: n = 104; placebo: n = 53), abemaciclib plus fulvestrant improved median PFS vs . placebo (11.41 months vs . 5.59 months, HR: 0.480; 95% CI: 0.322-0.715). Abemaciclib numerically improved ORR. Although immature, a trend toward OS benefit with abemaciclib was observed (cohort A: HR: 0.893, 95% CI: 0.553-1.443; cohort B: HR: 0.512, 95% CI: 0.281-0.931). The most frequent grade ≥3 adverse events in the abemaciclib arms were neutropenia, leukopenia, anemia (both cohorts), and lymphocytopenia (cohort B). Abemaciclib did not cause clinically meaningful changes in patient-reported global health, functioning, or most symptoms vs . placebo. CONCLUSIONS: Abemaciclib plus ET led to improvements in PFS and ORR, a manageable safety profile, and sustained HRQoL, providing clinical benefit without a high toxicity burden or reduced quality of life. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02763566).

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Figure 1 Kaplan–Meier plot of PFS in the ITT population in (A) cohort A and (B) cohort B. * HR stratified by nature of disease and prior ET; † Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; ‡ HR stratified by nature of disease, sensitivity to ET; § Log-rank stratified nominal P -value (two-sided) for comparison of treatment vs. placebo + fulvestrant. CI: Confidence interval; ET: Endocrine therapy; HR: Hazard ratio; ITT: Intention-to-treat; NSAI: Non-steroidal aromatase inhibitor; PFS: Progression-free survival.

A

PFS

Figure 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme upward reversal
查看结果
KM Figure2 个面板

Figure 4

Figure 4 Kaplan–Meier plots of TTD in mBPI-SF worst pain with increased analgesic use in (A) cohort A and (B) cohort B. TTD in pain was estimated using combined data from mBPI-SF and analgesic use, where deterioration in pain was defined as an increase of ≥2 points in mBPI-SF “worst pain” score from baseline (previously established as the minimally important difference), [26] or an increase of ≥1 level of analgesic drug class from baseline. † HR, stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ‡ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; § HR – stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ¶ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs . placebo + fulvestrant. 95% CI: 95% confidence interval; HR: Hazard ratio; mBPI-SF: Modified Brief Pain Inventory-Short Form; NSAI: Non-steroidal aromatase inhibitor; TTD: Time to deterioration; TTSD: Time to sustained deterioration.

A

Time to deterioration in pain

Figure 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Time to deterioration in pain

Figure 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2 PFS subgroup analysis in the ITT population in (A) cohort A and (B) cohort B. PFS HRs are indicated by diamonds and 95% CIs are indicated by the crossing horizontal lines. HRs were estimated using an unstratified Cox model with the treatment arm as a single covariate. Interaction P values were calculated from a separate Cox model with the treatment arm, subgroup factor, and their interaction term as independent variables. 95% CIs: 95% confidence intervals; AI: Aromatase inhibitor; DFI: Disease-free interval; DFI >12 months: Prior therapy with disease-free interval >2 months from completion of treatment; DFI ≤12 months: Prior therapy with disease-free interval ≤12 months from completion of treatment; ECOG PS: Eastern Cooperative Oncology Group performance status; ET: Endocrine therapy; HRs: Hazard ratios; ITT: Intention-to-treat; PFS: Progression-free survival; PgR: Progesterone receptor; PS: Performance status.
非 KM Figure
Figure 3Figure 3 Forest plots of TTSD of selected EORTC QLQ-C30 scales in (A) cohort A and (B) cohort B. TTSD was defined as the duration from randomization to the first occurrence of a ≥10-point deterioration in EORTC QLQ-C30 from baseline, followed by all subsequent scores meeting these thresholds. CI: Confidence interval; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; HR: Hazard ratio; TTSD: Time to sustained deterioration.
非 KM Figure
Figure 5Figure 5 Forest plots of TTSD in pain, as measured by the EORTC QLQ-C30, mBPI-SF alone, and mBPI-SF with analgesic use in (A) cohort A and (B) cohort B. TTSD was defined as the duration from randomization to the first occurrence of a ≥10-point deterioration in EORTC QLQ-C30 or an increase of ≥2 points in mBPI-SF from baseline, respectively, followed by all subsequent scores meeting these thresholds. CI: Confidence interval; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; HR: Hazard ratio; mBPI-SF: Modified Brief Pain Inventory-Short Form; TTSD: Time to sustained deterioration.
非 KM Figure